Astrum Therapeutics to begin clinical trials on Type 2 diabetes compounds
Friday, 29 July, 2005
Brisbane biotech BioProspect (ASX:BPO) has hit heavy cloud in its attempts to secure international partners to commercialise its novel plant-derived pesticides, but feels the sun is beginning to shine on its investment in Astrum Therapeutics.
BioProspect bought a one-third stake in Astrum on April 1, and the Melbourne drug-developer has announced it is moving to synthesise sufficient quantities of its two candidate compounds for treating Type 2 (non-insulin dependent) diabetes for clinical trials.
Astrum will begin recruiting volunteers for the trials by the end of the year -- it has not revealed the molecular targets for the molecules, but said they prevent the death of insulin-secreting pancreatic islet cells.
The company has also completed patent applications for combination therapies of its compounds, targeting the three major metabolic problems associated with type 2 diabetes -- cardiovascular disease, inflammation and neurological complications.
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
